Fujifilm to test stem cells in leukemia treatment
Nikkei - 23-Sep-2018A company is looking to start trials for induced stem cells to fight graft vs host disease
Previously the Live Forever Club — same community, now with a sharper mission for life extension
News provider covering Asian business, politics, economy and tech stories
Nikkei Asia brings you news and insights on the region's most influential companies, plus comprehensive coverage of politics, the economy, markets and trends - all from a uniquely Asian perspective.
For more than 140 years, Nikkei has been providing unparalleled coverage of Japan's economy, industries and markets. The group's business portfolio includes publishing, broadcasting and the Nikkei 225 stock index. Its flagship newspaper, The Nikkei, has a circulation of approximately 3 million. With 37 global bureaus and over 1,500 journalists, Nikkei is ideally positioned to provide Asian news and analysis to a global audience. The Financial Times(FT), the global business newspaper, joined the Nikkei group in 2015. As content partners, Nikkei Asia and the FT share select articles with their respective audiences and collaborate editorially on joint projects.
Visit website: https://asia.nikkei.com/
Details last updated 04-Feb-2019
A company is looking to start trials for induced stem cells to fight graft vs host disease